Target Price | $537.44 |
Price | $517.16 |
Potential | 3.92% |
Number of Estimates | 9 |
9 Analysts have issued a price target IDEXX Laboratories 2026 . The average IDEXX Laboratories target price is $537.44. This is 3.92% higher than the current stock price. The highest price target is $577.00 11.57% , the lowest is $510.00 1.38% . | |
A rating was issued by 13 analysts: 8 Analysts recommend IDEXX Laboratories to buy, 4 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2026 of 3.92% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
10 Analysts have issued a sales forecast IDEXX Laboratories 2025 . The average IDEXX Laboratories sales estimate is $4.1b . This is 5.13% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.2b 6.01% , the lowest is $4.1b 4.52% .
This results in the following potential growth metrics:
2024 | $3.9b | 6.46% |
---|---|---|
2025 | $4.1b | 6.05% |
2026 | $4.5b | 7.86% |
2027 | $4.8b | 8.67% |
2028 | $5.3b | 8.43% |
7 Analysts have issued an IDEXX Laboratories EBITDA forecast 2025. The average IDEXX Laboratories EBITDA estimate is $1.5b . This is 13.51% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.6b 24.34% , the lowest is $1.4b 6.70% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.3b | 4.09% |
---|---|---|
2025 | $1.5b | 15.77% |
2026 | $1.6b | 9.70% |
2027 | $1.7b | 8.96% |
2028 | $1.9b | 10.04% |
2024 | 32.40% | 2.23% |
---|---|---|
2025 | 35.21% | 9.17% |
2026 | 35.81% | 1.70% |
2027 | 35.91% | 0.28% |
2028 | 36.44% | 1.48% |
11 IDEXX Laboratories Analysts have issued a net profit forecast 2025. The average IDEXX Laboratories net profit estimate is $981m . This is 12.32% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $994m 13.77% , the lowest is $957m 9.60% .
This results in the following potential growth metrics and future Net Margins:
2024 | $861m | 6.06% |
---|---|---|
2025 | $981m | 13.90% |
2026 | $1.1b | 12.33% |
2027 | $1.3b | 13.60% |
2028 | $1.4b | 13.06% |
2024 | 22.10% | 0.37% |
---|---|---|
2025 | 23.74% | 7.40% |
2026 | 24.73% | 4.17% |
2027 | 25.85% | 4.53% |
2028 | 26.95% | 4.26% |
11 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is $12.15 . This is 12.29% higher than earnings per share in the financial year 2024. The highest EPS forecast is $12.31 13.77% , the lowest is $11.86 9.61% .
This results in the following potential growth metrics and future valuations:
2024 | $10.67 | 6.06% |
---|---|---|
2025 | $12.15 | 13.87% |
2026 | $13.65 | 12.35% |
2027 | $15.51 | 13.63% |
2028 | $17.53 | 13.02% |
Current | 47.79 | 9.25% |
---|---|---|
2025 | 42.55 | 10.96% |
2026 | 37.88 | 10.98% |
2027 | 33.35 | 11.96% |
2028 | 29.50 | 11.54% |
Based on analysts' sales estimates for 2025, the IDEXX Laboratories stock is valued at an EV/Sales of 10.28 and an P/S ratio of 10.06 .
This results in the following potential growth metrics and future valuations:
Current | 10.81 | 11.61% |
---|---|---|
2025 | 10.28 | 4.91% |
2026 | 9.53 | 7.29% |
2027 | 8.77 | 7.97% |
2028 | 8.09 | 7.77% |
Current | 10.58 | 12.21% |
---|---|---|
2025 | 10.06 | 4.88% |
2026 | 9.33 | 7.28% |
2027 | 8.59 | 7.98% |
2028 | 7.92 | 7.77% |
IDEXX Laboratories...
Analyst | Rating | Action | Date |
---|---|---|---|
Stifel |
Hold
➜
Hold
|
Unchanged | May 19 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | May 05 2025 |
Stifel |
Hold
➜
Hold
|
Unchanged | Apr 14 2025 |
Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Feb 10 2025 |
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Feb 04 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 04 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jan 29 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Stifel:
Hold
➜
Hold
|
May 19 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
May 05 2025 |
Unchanged
Stifel:
Hold
➜
Hold
|
Apr 14 2025 |
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Feb 10 2025 |
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Feb 04 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 04 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jan 29 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.